Brief: Aerovate Therapeutics reports Q2 results
15/08/2022 12:54
Aug 15 (Reuters) - Aerovate Therapeutics Inc AVTE.O :
* AEROVATE THERAPEUTICS ANNOUNCES SECOND QUARTER 2022
FINANCIAL
RESULTS
* AEROVATE THERAPEUTICS INC- QTRLY LOSS PER SHARE $0.49
* AEROVATE THERAPEUTICS - CASH, CASH EQUIVALENTS &
SHORT-TERM
INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS INTO H2 2025,
BASED ON CURRENT OPERATING PLAN
* AEROVATE THERAPEUTICS INC- EXPECT TO REPORT TOPLINE DATA
FROM
PHASE 2B PORTION OF IMPAHCT TRIAL IN Q4 OF 2023 OR Q1 OF 2024
Source text for Eikon: ID:nGNX2LhTnW
Further company coverage: AVTE.O
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million